This is a significant milestone for the company as it will generate long-term revenues with management expecting income of £500,000 to be realised in the first 12 months.
Shares in Glaxo SmithKline rose 2% after phase III trials were announced and after an upgrade by Swiss bank UBS
Changes to regulations in Australia have opened the door for cannabis breeders.
The CLV joint venture will immediately start developing a premium four-beer range.
Study represents another step towards the commercialisation of ResAppDx in the US.
Study of cannabinoid disposition in pediatric patients to assist autism research.